Marksans Pharma arm Relonchem bags UK MHRA marketing nod for oral solution to treat epilepsy
Written By : Ruchika Sharma
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2024-05-28 10:19 GMT | Update On 2024-05-28 10:19 GMT
Advertisement
Mumbai: Marksans Pharma Limited has announced that its wholly owned subsidiary Relonchem Limited has received Marketing Authorization for the product Levetiracetam Relonchem 100 mg/mL Oral Solution from the Medicines and Healthcare Products Regulatory Agency in the United Kingdom (UK MHRA).
Levetiracetam, a medication used for the treatment of epilepsy, helps in managing specific seizure types.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.